Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Bioniche E. coli Vaccine Granted Import Access to Australia

December 12, 2011

- Australian Quarantine and Inspection Service (AQIS) issues permit to
import Econiche
(TM) -

BELLEVILLE, ON, Dec. 12, 2011 /PRNewswire/ – Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that the Australian
Quarantine and Inspection Service (AQIS) has granted an import permit
for the Company’s E. coli O157 cattle vaccine – Econiche(TM).

The AQIS permit is a necessary first step in gaining access to the
Australian market. The vaccine will require regulatory review by the
Australian Pesticides and Veterinary Medicines Authority (APVMA). The
Company is preparing a regulatory dossier for submission to the APVMA
in coming months.

There are approximately 38 million cattle in Australia and New Zealand
(FAOStat). “Australia enjoys an estimated A$4.9 billion beef export
market,” said Mr. Rick Culbert, President of Bioniche Food Safety. “A
vaccine such as Econiche(TM )would add further protective measures to preserve and enhance the
reputation of Australian beef exports to key customers such as Japan,
the U.S. and Korea.”

Econiche(TM) has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle. E. coli O157 does not cause illness in cattle, but cattle are the primary
reservoir for it. Vaccination of cattle with Econiche(TM) can help reduce the risk of food and waterborne contamination with E. coli O157. The Company has been actively exploring opportunities to
introduce Econiche(TM) to markets beyond North America, where it has a full license in Canada
and a pending conditional license in the U.S.

The Econiche(TM) vaccine is currently produced in a product development laboratory at
the Company’s Belleville, Ontario headquarters. The new Animal Health
and Food Safety Vaccine Manufacturing Centre (VMC) in Belleville
continues to undergo validation and commissioning. This process is
expected to be completed by early 2012, after which production scale-up
will occur whereby Econiche(TM )will be moved into the VMC fermentors. It is expected that a first
commercial batch of the product will be made in the VMC by mid-2012.

About E. coli O157

E. coli O157 can cause severe illness and can even be fatal when ingested by
humans from contaminated meat, vegetables, other food products, or
water. Human exposure and infection with E. coli O157 can result in serious health consequences, including abdominal
pain and severe bloody diarrhea. In severe cases, kidney damage can
occur and progress to serious complications and even death. Lingering,
long-term medical conditions can persist in individuals exposed to the
bacterium. These include post-infectious irritable bowel syndrome
(PI-IBS), reduced kidney function, diabetes, hypertension and reactive
arthritis.

An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per
cent of those people develop haemolytic uremic syndrome (HUS), a
disease characterized by kidney failure. Five percent of HUS patients
die, many of them children and senior citizens, whose kidneys are more
sensitive to damage. Among the many outbreaks recorded, a 1996 Japanese
outbreak made more than 9,000 people sick while the Walkerton, Ontario
outbreak in 2000 sickened 2,500. Recent outbreaks have been tied to
romaine lettuce in the U.S., a state fair in the U.S., and a nursery
school in North Wales.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company’s primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
value.

Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2010. For more information,
please visit www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.

SOURCE Bioniche Life Sciences Inc.


Source: PR Newswire